Scheduling, administration, biomarkers, and practical guidance.
4–6 weeks ON, 2–4 weeks OFF. Minimises overstimulation and side effect risk while assessing individual sensitivity.
1–2× daily; 6–8 weeks ON. Standard clinical range for nerve injury and systemic neuro-inflammation.
SubQ or high-dose oral; 8–12 weeks ON for chronic cases. Higher risk of nausea, headache. Clinical supervision required.
Standard cognitive enhancement range. Higher doses used in clinical stroke recovery under medical supervision.
Wellness and cognitive optimisation range. 4–8 week cycles followed by rest period. Note: 12-day half-life in animal models — start low.
Clinical setting only. Repeated in cycles every few months for chronic neurodegenerative conditions.
Rest period prevents potential receptor desensitisation. BPC-157 induces structural changes that persist after discontinuation — extended continuous use is unnecessary.